Indicators

Latest News about IONS

Recent news which mentions IONS

< Previous 1 2 3 4 5 6 Next >

Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)

June 03, 2024

Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile

May 31, 2024

Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder

May 31, 2024

Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another

May 16, 2024

The 3 Most Undervalued Pharma Stocks to Buy in May 2024

May 09, 2024

The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals

May 08, 2024

IONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024

May 07, 2024

The Latest Analyst Ratings For Ionis Pharmaceuticals

April 09, 2024

Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows

March 13, 2024

Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals

February 22, 2024

Earnings Scheduled For February 21, 2024

February 21, 2024

JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know

February 01, 2024

Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines

January 31, 2024

Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study

January 22, 2024

Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts

January 18, 2024

2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs

January 04, 2024

10 Health Care Stocks Whale Activity In Today's Session

January 02, 2024

3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar Companies

December 27, 2023

Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential

December 22, 2023

New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment

December 22, 2023

Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach

December 19, 2023

Where Ionis Pharmaceuticals Stands With Analysts

November 17, 2023

Cathie Wood's Ark Invest Goes Shopping For Moderna Stock — Sells DraftKings Shares Amid Quarterly Rise In Revenue, EPS Beat

November 02, 2023

Analyst Expectations for Ionis Pharmaceuticals's Future

October 23, 2023

Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On?

October 17, 2023

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023

September 29, 2023

Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges

September 27, 2023

Analyst Expectations for Ionis Pharmaceuticals's Future

September 27, 2023

Why Ionis Pharmaceuticals Stock Popped Today

September 26, 2023

Ionis Pharmaceuticals' Rare Metabolic Disorder Candidate Poised To Become New Standard Treatment, Study Shows Encouraging Action

September 26, 2023

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.